Literature DB >> 16061684

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

Annemieke Th den Boer1, Geertje J D van Mierlo, Marieke F Fransen, Cornelis J M Melief, Rienk Offringa, René E M Toes.   

Abstract

Modulation of the immune response by established tumors may contribute to the limited success of therapeutic vaccination for the treatment of cancer compared with vaccination in a preventive setting. We analyzed the contribution of the CD4+ T-cell population to the induction or suppression of tumor-specific CD8+ T cells in a tumor model in which eradication of tumors crucially depends on CD8+ T cell-mediated immunity. Vaccine-mediated induction of protective antitumor immunity in the preventive setting (i.e., before tumor challenge) was CD4+ T cell dependent because depletion of this T-cell subset prevented CD8+ T-cell induction. In contrast, depletion of CD4+ cells in mice bearing established E1A+ tumors empowered the mice to raise strong CD8+ T-cell immunity capable of tumor eradication without the need for tumor-specific vaccination. Spontaneous eradication of tumors, which had initially grown out, was similarly observed in MHC class II-deficient mice, supporting the notion that the tumor-bearing mice harbor a class II MHC-restricted CD4+ T-cell subset capable of suppressing a tumor-specific CD8+ T-cell immune response. The deleterious effects of the presence of CD4+ T cells in tumor-bearing hosts could be overcome by CD40-triggering or injection of CpG. Together these results show that CD4+ T cells with a suppressive activity are rapidly induced following tumor development and that their suppressive effect can be overcome by agents that activate professional antigen-presenting cells. These observations are important for the development of immune interventions aiming at treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061684     DOI: 10.1158/0008-5472.CAN-04-3344

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

2.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

3.  A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Authors:  Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Kimberly A Chianese-Bullock; Ileana S Mauldin; Kelly T Smith; Donna H Deacon; Nikole E Varhegyi; Sean B Donnelly; Caroline M Reed; Kristy Scott; Nadejda V Galeassi; William W Grosh
Journal:  Cancer Immunol Immunother       Date:  2015-11-18       Impact factor: 6.968

Review 4.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth.

Authors:  Dmitrij Ostroumov; Nora Fekete-Drimusz; Michael Saborowski; Florian Kühnel; Norman Woller
Journal:  Cell Mol Life Sci       Date:  2017-10-14       Impact factor: 9.261

Review 5.  Differential role of CXCR3 in inflammation and colorectal cancer.

Authors:  Jessicca D Abron; Narendra P Singh; Angela E Murphy; Manoj K Mishra; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh
Journal:  Oncotarget       Date:  2018-04-03

6.  Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model.

Authors:  Norihiro Fujinami; Toshiaki Yoshikawa; Yu Sawada; Manami Shimomura; Tatsuaki Iwama; Shiori Sugai; Shigehisa Kitano; Yasushi Uemura; Tetsuya Nakatsura
Journal:  Biochem Biophys Rep       Date:  2016-02-19

7.  TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration.

Authors:  Hiroyasu Aoki; Satoshi Ueha; Shigeyuki Shichino; Haru Ogiwara; Shin-Ichi Hashimoto; Kazuhiro Kakimi; Satoru Ito; Kouji Matsushima
Journal:  Front Immunol       Date:  2019-01-24       Impact factor: 7.561

8.  First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.

Authors:  Kohei Shitara; Satoshi Ueha; Shigeyuki Shichino; Hiroyasu Aoki; Haru Ogiwara; Tetsuya Nakatsura; Toshihiro Suzuki; Manami Shimomura; Toshiaki Yoshikawa; Kayoko Shoda; Shigehisa Kitano; Makiko Yamashita; Takayuki Nakayama; Akihiro Sato; Sakiko Kuroda; Masashi Wakabayashi; Shogo Nomura; Shoji Yokochi; Satoru Ito; Kouji Matsushima; Toshihiko Doi
Journal:  J Immunother Cancer       Date:  2019-07-24       Impact factor: 13.751

9.  Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chi-An Chen; Han-Wei Lin; Wen-Fang Cheng; Chung-Liang Chien
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

10.  An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects.

Authors:  Hyun-Il Cho; Soo-Hyun Jung; Hyun-Jung Sohn; Esteban Celis; Tai-Gyu Kim
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.